Since absence of expression of the c-src gene product in mice indicates that the pp60CSF" tyrosine kinase is required and essential for osteoclastic bone resorption, we tested the effects of the antibiotic herbimycin A, which is an inhibitor of pp60 " on osteoclastic bone resorption in vitro and on hypercalcemia in vivo. We examined the effects of herbimycin A on the formation of bone resorbing osteoclasts in mouse long-term marrow cultures, on isolated rodent osteoclasts and on bone resorption in organ cultures of fetal rat long bones stimulated by parathyroid hormone. We found that herbimycin A in concentrations of 1-100 ng/ml inhibited bone resorption in each of these systems. We determined the effects of herbimycin A ( 100 ng/ml) on src tyrosine kinase activity in mouse marrow cultures and found that it was decreased. Herbimycin A also decreased elevated blood calcium levels that were induced either by repeated subcutaneous injections of recombinant human interleukin-la or by a human tumor. There was no evidence for toxicity in any of these culture systems or in mice treated with herbimycin A. A different tyrosine kinase inhibitor that does not inhibit pp6j(f was used as a control and caused none of these effects. These data suggest that pp6O45w tyrosine kinase inhibitors may be useful pharmacologic inhibitors of osteoclastic bone resorption and hypercalcemia. (J. Clin. Invest. 1993.91:2791-2795
Introduction
Recent observations suggest that different tyrosine kinases (TKs)' may be essential for normal osteoclastic bone resorption. Mice deficient in expression ofthe c-src protooncogene by introduction ofthe null mutation into the germ line by homolo- 1 . Abbreviations used in this paper: aPY, antiphosphotyrosine antibody; Ca2+, whole-blood ionized calcium; PTH, parathyroid hormone; rh-IL-i a, recombinant human IL-la; TK, tyrosine kinase; TRAP(+)MNC, tartrate-resistant acid phosphatase-positive multinucleated cells; 1,25D3, 1,25-dihydroxyvitamin D3.
gous recombination develop osteopetrosis ( 1 ). These data indicate that the TK encoded by src is required for normal osteoclast function. Recently, an antibiotic herbimycin A that inhibits a number ofintracellular TKs, including the src TK, has been identified. This antibiotic has been shown to reverse temperature sensitive respiratory syncytial virus (RSV)-transformed rat cells (ts/NRK) morphology to normal, concomitant with a marked reduction in pp6Osrc kinase activity. Herbimycin A irreversibly and directly inhibits pp6O-src TK but has no effects on serine/threonine kinase, protein kinase A, and protein kinase C (2). To determine if herbimycin A could be a useful inhibitor of osteoclastic bone resorption, we tested its effects on bone resorption stimulated by parathyroid hormone (PTH) in three different in vitro systems that examine different aspects of osteoclast function, namely osteoclast formation, as well as osteoclastic activation and resorption. We also found that herbimycin A inhibited hypercalcemia in mice that was induced either by repeated injections of recombinant human IL-1 a (rhIL-1 a) or by a human tumor. We examined another TK inhibitor, RG-13022 (3, 4) , as a control. RG-13022 showed none of these effects.
Methods Drugs
RG-1 3022 was kindly supplied by Dr. A. Zilberstein (Rhone-Poulenc Rorer Biotechnology, Collegeville, PA). Fig. 1 shows the structure of herbimycin A and RG-13022. Stock solutions of the drugs were made in 100% DMSO and diluted with the culture medium before addition to cells. The culture medium containing the equivalent concentrations of DMSO served as vehicle controls.
Fetal rat long bone assay
This assay measures the release of previously incorporated 45Ca from fetal rat long bones in organ culture, and has been described previously (5) . Four bones were cultured per group, and bone resorbing activity was expressed as treated: control ratios of 45Ca released from test and control bones. Statistical significance was assessed using the Student's t test for unpaired samples.
Murine marrow cell culture system
We used a modification of the murine marrow culture technique described by Takahashi et al. (6) Assayfor pp60c'src protein kinases
The assays were performed as described ( 12 Administration ofherbimycin A and RG-13022 to animals rhIL-la-injected mice. ICR Swiss white mice (Harlan Sprague-Dawley, Indianapolis, IN) were injected subcutaneously over the right side ofthe calvariae with 10Mg herbimycin A or RG-13022 in 10 ul DMSO or DMSO alone four times a day using 27-gauge needles. 30 min later of each injection of herbimycin A or RG-13022, some of the mice received subcutaneous injections of0.1 Mug recombinant human IL-la, kindly supplied by Dr. Lomedico (Hoffman-La Roche, Nutley, NJ) in 10 Ml PBS four times a day over the right side of the calvariae as described previously ( 14) .
Tumor-bearing mice. Nude mice (BALB/c nu/nu; Sprague-Dawley) bearing a well-characterized human squamous cancer MH-85 (15) that manifested hypercalcemia were injected intraperitoneally with 100 Mg herbimycin A in 0.1 ml DMSO twice a day.
Determination ofblood-ionized Ca (Ca2") and body weight. Ca2" was determined using a calcium pH analyzer (model 634; Corning, Medfield, MA) as described ( 15) . Body weight of animals was measured (Lum-O-Gram; Ohaus Scale Corporation, Florham Park, NJ). These measurements were carried out at 9:00 a.m. every other day before the first injection of agents under anesthesia. Statistical analysis. All data shown are mean±SE and were analyzed by ANOVA followed by a paired t test. (Fig. 2) . This effect is unlikely to be caused by the cytotoxicity of herbimycin A. Number of stromal cells harvested by trypsinization in control and herbimycin A-treated (100 ng/ml) marrow cultures at day 6 was not different (control/treated = 3.2±0.3:2.9±0.3 x 106/ well, n = 4) and 3H-amino acid incorporation into TCA-insoluble protein in herbimycin A-treated (100 ng/ml) cultures was not changed (control/treated = 4.2±0.5:3.9±0.2 x 103 dpm/well, n = 4). In the same cultures, PTH increased apparent activity of pp6Ocsrc TK, which was measured using enolase as a substrate in bone marrow cell lysates immunoprecipitated with the 327 monoclonal antibody to pp6Ocsrc. Herbimycin A markedly decreased the activity of pp6Ocsrc TK, which was increased by PTH (Fig. 3 ). There were no significant differences in size, shape and nuclear number of TRAP ( pp6Oc-src TK protein levels determined by Western analysis in mouse marrow cultures (data not shown). Next, we examined the effects of herbimycin A on the capacity of disaggregated rat osteoclasts to form resorption pits on dentine. Herbimycin A decreased the area ofpits formed by disaggregated osteoclasts treated with PTH in a dose-dependent manner from 1 to 100 ng/ml (Fig. 4) . Herbimycin A showed no effects on the number of pits formed (Fig. 4) . Herbimycin A also inhibited PTH-stimulated bone resorption of fetal rat long bones in organ cultures (Fig. 5) . RG-13022 did not show such an effect in the same assay (Fig. 5, data Herbimycin A(ng/ml) Figure 4 . Effect of herbimycin A on resorption pit formation by isolated rat osteoclasts. Isolated osteoclasts were cultured on the dentine slices in the absence or presence of 50 ng/ml PTH with or without herbimycin A for 24 h. Pit number (top) and pit area (bottom) were then determined as described in Methods. Data shown are mean±SE.
*Significantly greater than control (P < 0.05). **Significantly less than cultures treated with PTH alone (P < 0.01). Figure 5 . Effect of herbimycin A and RG-1 3022 on bone resorption in organ cultures of fetal rat long bones. Fetal rat long bones were cultured in the absence or presence of 50 ng/ml PTH with or without 0.1 gg/ml herbimycin A or 20 ;iM (5.36 Ag/ml) RG-l 3022 for 120 h. Values shown are mean±SE. *Significantly higher than control (P < 0.01 ). **Significantly less than cultures treated with PTH alone (P < 0.01).
mouse (Fig. 6) . Previous studies have shown this is caused by increased osteoclastic bone resorption (14) . Simultaneous treatment with subcutaneous injections of herbimycin A (10 ,ug/mouse per injection, four injections a day) markedly prevented the development of hypercalcemia induced by rhIL-1 a (Fig. 6) .
In preliminary experiments, we found that repeated subcutaneous injections of 400, 200, and 100 ,ug herbimycin A/ mouse per day into untreated ICR Swiss mice killed the animals after 1-3 d. However, administration of herbimycin A at 40 ug/mouse per day as shown in Fig. 6 did not show any significant effects on viability, food consumption, body weight, and behavior of animals (data not shown).
RG-13022 (10 ,tg/mouse per day) administered in the same manner as that of herbimycin A did not decrease Ca21 in rhIL-la-treated mice (Fig. 6 ). 
Discussion
The data reported in this paper show that herbimycin A, which is known to inhibit pp6Ocsrc TK activity (2), decreased pp6Ocsrc TK activities in mouse bone marrow cells and inhibited the formation of cells with osteoclast characteristics and their bone resorbing capacity in the same culture system. Furthermore, herbimycin A inhibited the capacity of mature osteoclasts to form pits on dentine slices and suppressed bone resorption in organ cultures of fetal rat long bones. More importantly, we found that herbimycin A decreased and prevented rhIL-la-or tumor-induced hypercalcemia, both of which are associated with increased osteoclastic bone resorption in vivo (14, 15 None of the currently available inhibitors of bone resorption are entirely satisfactory. Estrogens have only been used effectively in postmenopausal females and the mode of action ofestrogen remains unclear. Bisphosphonates are effective, but are absorbed poorly when used orally. Again, their mode of action to inhibit bone resorption remains uncertain. In the case of herbimycin A, its inhibitory effects on bone resorption are most likely due to its capacity to inhibit pp60-src TKs, and this or related TK inhibitors that can be used orally may be useful therapies in common diseases of increased osteoclast activity such as postmenopausal osteoporosis, hypercalcemia of malignancy, and Paget's disease.
Although herbimycin A has been shown to inhibit pp6Ocsrc TK and have no effects on protein kinase A and protein kinase C (2), its absolute specificity for pp6Osrc TK is unknown. Since pp6Ocsrc TK is increased in active osteoclasts during bone resorption, it seems likely that the effects ofherbimycin A to inhibit bone resorption are related to its capacity to inhibit pp6Oc-src TK.
Toxicity was not likely to account for the effects we observed. Since herbimycin A is an irreversible inhibitor of pp6OCSC, we were not able to exclude toxicity by showing that transient exposure to herbimycin A would not impair bone resorption stimulated by PTH. However, herbimycin A did not affect the numbers of stromal cells and pits formed by osteoclasts, decrease protein synthesis by marrow cells, cause detachment of osteoclasts or stromal cells from either plastic culture dishes or dentine, or reduce control resorption in the organ culture assays. Herbimycin A-treated animals did not manifest any marked changes in food consumption, body weight, and motional activity.
In conclusion, our data suggest that herbimycin A may have therapeutic potential as a bone resorption inhibitor in disease states where bone resorption is enhanced.
